Lux Capital
Check: Firm-level: Lux says it can invest from an initial $100K through high-conviction follow-ons as large as $100M across the company-building arc. This is not David's personal standard check range.
David backs scientific founders in therapeutics, R&D tooling, and biopharma infrastructure, looking for research edges early enough to matter. His research and company-building background supports a translational lens: find important science before it is broadly distributed, test whether the platform creates a repeatable advantage rather than a single asset, and build the operational infrastructure required to turn experimental insight into durable medicines or tools.
InceptionPre-SeedSeed